These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29410937)

  • 1. Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors.
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Innov Clin Neurosci; 2017 Dec; 14(11-12):54-58. PubMed ID: 29410937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM).
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Psychiatry Res; 2020 Dec; 294():113569. PubMed ID: 33223272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
    Haddad PM; Correll CU
    Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
    Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
    CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo?
    Daniel DG; Kott A; Saoud J; Luthringer R; Rud V; Skyrpnikov A; Stan R; Palazov V; Wang X; Davidson M
    Innov Clin Neurosci; 2020 Jan; 17(1-3):27-29. PubMed ID: 32547844
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
    Allen MH; Citrome L; Pikalov A; Hsu J; Loebel A
    Gen Hosp Psychiatry; 2017 Jul; 47():75-82. PubMed ID: 28807142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
    Citrome L; Meng X; Hochfeld M
    Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
    Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
    Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].
    Mosolov SN; Malyutin AV; Pikalov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(12):29-37. PubMed ID: 31994511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
    Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
    Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
    Rekhi G; Alphs L; Ang MS; Lee J
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1433-1441. PubMed ID: 31761524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.